PATENT CLAIM ANALYSIS

Application Number: 15879056
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

Claim (Index 44):
The bispecific molecule of  claim 42 , wherein said diabody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein:\n (A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:\n (i) a domain (A) comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for an epitope (1); \n (ii) a domain (B) comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for an epitope (2); and\n (iii) a domain (C) comprising a cysteine residue and an E coil or a K coil; \n (B) said second polypeptide chain comprises, in the N-Terminal to C-terminal direction:\n (i) a domain (D) comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) specific for epitope (2); \n (ii) a domain (E) comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) specific for epitope (1); \n (iii) a domain (F) comprising a cysteine residue and a K coil if the first polypeptide has an E coil, or a cysteine residue and an E coil if the first polypeptide has a K coil; and \n (iv) a CH2\u2014CH3 region of an Fc region; \n (C) said third polypeptide chain comprises a CH2\u2014CH3 region of an Fc region; wherein: (1) said domains (A) and (B) do not associate with one another to form an epitope-binding domain; (2) said domains (D) and (E) do not associate with one another to form an epitope-binding domain; (3) said domains (A) and (E) associate to form an epitope-binding domain that binds epitope (1); (4) said domains (B) and (D) associate to form an epitope-binding domain that binds said epitope (2), and wherein:\n (a) said epitope (1) is said epitope of an activating receptor of an immune effector cell and said epitope (2) is said epitope of an antigen expressed by a cell infected with a virus; or \n (b) said epitope (1) is said epitope of an antigen expressed by a cell infected with a virus and said epitope (2) is said epitope of an activating receptor of an immune effector cell; and \n (5) said domains (C) and (F) are covalently associated together by a disulfide bond.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 86.0
- Lexical Diversity: 2.13333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14775041', '15313741', '15313765', '14637194', '13811883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7058660345274006
- 35 USC 102 Novelty (BERT): 0.703461613051883
- Combined Prediction Score: 0.7056255923798489
- Mean Citation Score: 492.93482000000006
- Max Citation Score: 826.9506
- Similarity Product: 718.6027851659061

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test